NGM BIOPHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -1.28% |
|
0.00% | +79.28% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,221 | 2,090 | 1,376 | 410.3 | 71.05 | 128.5 |
| Enterprise Value (EV) 1 | 975.6 | 1,943 | 1,224 | 336.8 | 15.24 | 128.5 |
| P/E ratio | -21.8 x | -20.2 x | -11.4 x | -2.47 x | -0.5 x | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11,794,185 x | 23,924,953 x | 17,670,680 x | 7,414,474 x | 16,086,172 x | - |
| EV / Revenue | 11,794,183 x | 23,924,952 x | 17,670,678 x | 7,414,473 x | 16,086,159 x | - |
| EV / EBITDA | -29,261,216 x | -21,487,645 x | -12,008,339 x | -2,529,159 x | -470,718 x | - |
| EV / FCF | -27,342,920 x | -24,483,457 x | -18,371,013 x | -2,804,330 x | -532,412 x | - |
| FCF Yield | -0% | -0% | -0% | -0% | -0% | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 66,047 | 68,997 | 77,709 | 81,726 | 82,716 | 83,462 |
| Reference price 2 | 18.49 | 30.30 | 17.71 | 5.020 | 0.8590 | 1.540 |
| Announcement Date | 3/17/20 | 3/4/21 | 3/1/22 | 2/28/23 | 3/11/24 | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2026 |
|---|---|---|---|---|---|---|
| Net sales | 103.5 | 87.37 | 77.88 | 55.33 | 4.417 | - |
| EBITDA | -41.74 | -97.28 | -114.6 | -162.2 | -150.9 | - |
| EBIT | -49.34 | -103.8 | -120.3 | -166.2 | -151.5 | - |
| Operating Margin | -47.65% | -118.85% | -154.51% | -300.45% | -3,429.09% | - |
| Earnings before Tax (EBT) | -42.8 | -102.5 | -120.3 | -162.7 | -142.4 | - |
| Net income | -42.8 | -102.5 | -120.3 | -162.7 | -142.4 | - |
| Net margin | -41.33% | -117.3% | -154.51% | -293.98% | -3,223.34% | - |
| EPS | -0.8500 | -1.500 | -1.560 | -2.030 | -1.730 | - |
| Free Cash Flow | -44.66 | -85.38 | -74.91 | -146.3 | -133.5 | - |
| FCF margin | -43.13% | -97.72% | -96.19% | -264.39% | -3,021.37% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/4/21 | 3/1/22 | 2/28/23 | 3/11/24 | - |
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 246 | 147 | 152 | 73.5 | 55.8 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | -44.7 | -85.4 | -74.9 | -146 | -133 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | -69.8% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | 3.49 | 1.88 | 1.68 | 1.86 | 1.25 | - |
| Capex / Sales | 3.37% | 2.15% | 2.16% | 3.36% | 28.35% | - |
| Announcement Date | 3/17/20 | 3/4/21 | 3/1/22 | 2/28/23 | 3/11/24 | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +79.28% | 129M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- NGM Stock
- Financials NGM Biopharmaceuticals, Inc.
